What is Eli Lilly's stock-based comp?

Eli Lilly (LLY) reported stock-based comp of $161M in Q1 2026.

How has Eli Lilly's stock-based comp changed year-over-year?

Eli Lilly's stock-based comp increased by 4.5% year-over-year, from $154M to $161M.

What is the long-term trend for Eli Lilly's stock-based comp?

Over 4 years (2021 to 2025), Eli Lilly's stock-based comp has grown at a 16.2% compound annual growth rate (CAGR), from $342.8M to $626M.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Eli Lilly LLY Stock-Based Comp

Stock-Based Comp at other companies

PfizerPFE

$272M+60.0%

AmgenAMGN

$75M-11.8%

Cardinal HealthCAH

$129M+316%

MannkindMNKD

$6.46M+19.9%

Oruka Therapeutics, Inc.ORKA

$6.97M+42.7%

ExelixisEXEL

$29.05M+12.0%

Other financials

Income statement

See full

Revenue$19.8B+55.5%

Gross profit$16.2B+54.4%

Net income$7.4B+168%

EPS (diluted)$8.26+170%

Balance sheet

See full

Cash & equivalents$5.3B+70.8%

Total debt$43.4B+12.6%

Total equity$31.2B+97.9%

Total assets$116.58B+30.4%

Cash flow

See full

Operating cash flow$5.3B+220%

CapEx$2.3B+54.0%

Free cash flow$3.0B+1,828%

Valuation

See full

Market cap$1.08T+54.2%

Enterprise value$1.12T+51.7%

P/E42.6×-8.0×

P/S14.9×+1.8×

Profitability

See full

Gross margin82.8%+1.1pp

Net margin35%+12.3pp

FCF margin16.4%+8.7pp

Returns & leverage

See full

Return on equity107.6%+29.9pp

Debt / equity1.4×-1.1×

Current ratio1.5×+0.1×

Where this comes from

Reported directly by Eli Lilly in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Eli Lilly’s 10-Q, filed April 30, 2026, on SEC EDGAR. View the filing →

Ask your AI about Eli Lilly's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Eli Lilly's stock-based comp?: Eli Lilly (LLY) reported stock-based comp of $161M in Q1 2026.
How has Eli Lilly's stock-based comp changed year-over-year?: Eli Lilly's stock-based comp increased by 4.5% year-over-year, from $154M to $161M.
What is the long-term trend for Eli Lilly's stock-based comp?: Over 4 years (2021 to 2025), Eli Lilly's stock-based comp has grown at a 16.2% compound annual growth rate (CAGR), from $342.8M to $626M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.